Fredag 6 Juni | 18:43:27 Europe / Stockholm

Prenumeration

2025-06-04 08:42:00

Redeye return with a research update following BioArctic's Q1 report and capital markets day. We reiterate our positive long-term view but account for Eisai's latest Leqembi forecast and simulations as well as the weaker USD/SEK, leading to a slighly lower valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/